5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Urinary Tract Infection Therapeutics Market is segmented by drug (penicillin and combinations, quinolones, cephalosporin, azoles and amphotericin B, and nitrofurans), indication, and geography.
Fastest Growing Market:
The market is expected to witness a CAGR of 3.5% during the forecast period. Certain factors that are driving the market growth include the increasing prevalence of diabetes and kidney stones and the launch of combination drugs.
Urinary tract infection (UTI) affects the urinary tract. It is one of the most common bacterial infections, and it is more common in women, as compared to men. UTI is considered as one of the frequent causes of morbidity and mortality, globally.
|Penicillin and Combinations|
|Azoles and Amphotericin B|
|Other Drugs (Aminoglycoside Antibodies, Sulphonamides, Tetracycline, etc.)|
|Other Indications (Recurring Complicated UTI, Neurogenic Bladder Infection, etc.)|
Report scope can be customized per your requirements. Click here.
The prevalence of uncomplicated UTI is significantly higher, as compared to recurring complicated UTI. However, the prevalence of complicated UTI is expected to increase in the future, owing to the rise in drug-resistant bacteria and excessive use of antibiotics. A vast majority of physicians prescribe quinolones to treat complicated UTI cases. Cephalosporin is the second-most common drug prescribed for complicated UTI cases. Overall, the prevalence of complicated UTI is set to increase during the forecast period, mainly owing to the increasing bacterial resistance in UTI cases and rise in recurrence rate for UTI.
To understand key trends, Download Sample Report
The region is experiencing a drastic increase in innovations related to diagnostic methodologies used for UTIs. In recent events, during a routine checkup for UTI, a woman was observed to be infected by E. coli that showed resistance to the last-resort antibiotic, Colistin. The discovery of Colistin-resistant bacteria was considered a major issue. In addition to that, the CDC, in collaboration with other organizations, developed guidelines for the prevention of catheter-associated UTIs and other types of healthcare-associated infections in the United States.
To understand geography trends, Download Sample Report.
The urinary tract infection therapeutics market is highly competitive and consists of a number of major players. Companies, like AstraZeneca, Bayer AG, Cipla Inc., GlaxoSmithKline PLC, Merlion Pharma, Novartis AG, and Pfizer, among others, hold the substantial share of the market.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Diabetes and Kidney Stones
4.2.2 Launch of Combination Drugs
4.3 Market Restraints
4.3.1 Adverse Effects Associated with the Use of Medication
4.3.2 Lack of Awareness in the Developing and Underdeveloped Countries
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1.1 Penicillin and Combinations
5.1.4 Azoles and Amphotericin B
5.1.6 Other Drugs (Aminoglycoside Antibodies, Sulphonamides, Tetracycline, etc.)
5.2.1 Complicated UTI
5.2.2 Uncomplicated UTI
5.2.3 Other Indications (Recurring Complicated UTI, Neurogenic Bladder Infection, etc.)
5.3.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.3.4 Middle East & Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle East & Africa
5.3.5 South America
220.127.116.11 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.2 Bayer AG
6.1.3 Cipla Inc.
6.1.4 GlaxoSmithKline PLC
6.1.5 Merlion Pharma
6.1.6 Novartis AG
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments